We are live on
!
Find out more
RI
RTW Investments Portfolio holdings
AUM
$10B
1-Year Est. Return
135.35%
This Fund
S&P 500
This Quarter
Est. Return
+13.47%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$10B
AUM Growth
+$66.4M
(+0.67%)
Cap. Flow
+$419M
Cap. Flow
% of AUM
4.17%
Top 10 Holdings %
Top 10 Hldgs %
49.99%
Holding
98
New
7
Increased
30
Reduced
13
Closed
10
Top Buys
| 1 |
CG Oncology
CGON
|
+$282M |
| 2 |
Celcuity
CELC
|
+$271M |
| 3 |
Erasca
ERAS
|
+$189M |
| 4 |
Tango Therapeutics
TNGX
|
+$164M |
| 5 |
iRhythm Holdings
IRTC
|
+$70.2M |
Top Sells
| 1 |
Penumbra
PEN
|
+$269M |
| 2 |
Axsome Therapeutics
AXSM
|
+$162M |
| 3 |
Insulet
PODD
|
+$92.3M |
| 4 |
MASI
Masimo
MASI
|
+$88.9M |
| 5 |
APLS
Apellis Pharmaceuticals
APLS
|
+$85.8M |
Sector Composition
| 1 | Healthcare | 99.92% |
| 2 | Financials | 0.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Immatics
IMTX
$1.28B
| $127M | 1.26% |
12,869,340
+1,435,986
| +13% | +$14.1M |
|
27
Zai Lab
ZLAB
$2.31B
| $124M | 1.23% |
6,574,032
-385,000
| -6% | -$7.14M |
|
|
BLTE
28
Belite Bio
BLTE
$5.89B
| $114M | 1.13% |
715,332
| – | – |
|
29
Intuitive Surgical
ISRG
$143B
| $101M | 1.01% |
220,000
+118,772
| +117% | +$60.1M |
|
|
ORKA
30
Oruka Therapeutics
ORKA
$5.09B
| $101M | 1% |
2,058,148
| – | – |
|
31
GH Research
GHRS
$1.96B
| $83.4M | 0.83% |
5,933,815
| – | – |
|
32
Xencor
XNCR
$1.09B
| $81.7M | 0.81% |
6,777,461
| – | – |
|
33
UroGen Pharma
URGN
$1.93B
| $81.7M | 0.81% |
4,543,895
| – | – |
|
|
CNTA
34
DELISTED
Centessa Pharmaceuticals
CNTA
| $81.6M | 0.81% |
2,054,175
+263,338
| +15% | +$6.74M |
|
35
Immunovant
IMVT
$8B
| $78.9M | 0.79% |
3,177,849
-1
| -0% | -$26 |
|
36
Ultragenyx Pharmaceutical
RARE
$3.1B
| $76.4M | 0.76% |
3,648,795
+648,656
| +22% | +$14.6M |
|
|
HNGE
37
Hinge Health
HNGE
$6.61B
| $74.4M | 0.74% |
1,930,000
+1,576,500
| +446% | +$65.5M |
|
38
Castle Biosciences
CSTL
$757M
| $67.7M | 0.67% |
2,758,335
+643,098
| +30% | +$21.1M |
|
39
Rocket Pharmaceuticals
RCKT
$388M
| $63.3M | 0.63% |
17,687,772
| – | – |
|
40
Taysha Gene Therapies
TSHA
$1.77B
| $61.2M | 0.61% |
13,680,248
-2,718,049
| -17% | -$12.6M |
|
41
Alkermes
ALKS
$8.67B
| $59.1M | 0.59% |
1,672,356
| – | – |
|
|
CMPS
42
Compass Pathways
CMPS
$1.81B
| $58.8M | 0.59% |
10,632,390
+1,875,000
| +21% | +$12.6M |
|
43
Kodiak Sciences
KOD
$2.62B
| $56.7M | 0.56% |
1,487,934
+1
| +0% | +$26 |
|
44
Replimune Group
REPL
$792M
| $56.3M | 0.56% |
7,356,916
+216,564
| +3% | +$1.66M |
|
45
Crinetics Pharmaceuticals
CRNX
$8.88B
| $52.7M | 0.52% |
1,451,326
+100,000
| +7% | +$4.47M |
|
46
uniQure
QURE
$2.74B
| $42.3M | 0.42% |
2,586,356
-1,125,106
| -30% | -$22.8M |
|
|
WAY
47
Waystar Holding Corp
WAY
$4.41B
| $39.3M | 0.39% |
+1,630,000
| New | +$43.3M |
|
48
Arrowhead Research
ARWR
$9.93B
| $36.7M | 0.37% |
585,682
+966
| +0.2% | +$61.1K |
|
49
Orchestra BioMed
OBIO
$219M
| $35.3M | 0.35% |
8,306,063
| – | – |
|
50
Verastem
VSTM
$499M
| $34.9M | 0.35% |
6,576,306
| – | – |
|
Similar funds
BEI
ECM
BHCM
MG
LWCFA
HRCM
RA
VNIM